Michal Oleksiejczuk Accepts 1-Year USADA Suspension for Failed Drug Test at UFC 219
Light heavyweight Michal
Oleksiejczuk has accepted a one-year suspension from USADA for
failing an in-competition drug test at UFC 219 this past
December.
The sanction is the same length of the one handed down by the Nevada Athletic Commission earlier this year. The NAC also fined Oleksiejczuk 30 percent of his $12,000 purse and overturned his decision victory over Khalil Rountree to a no contest.
The 23-year-old Barki, Poland, native tested positive for
clomiphene, an estrogen blocker which can be used in tandem with
performance enhancing drugs. Oleksiejczuk’s suspension is
retroactive to Dec. 30, so he will able to return at the end of
2018.
Oleksiejczuk, who was a short-notice replacement for Gokhan Saki at UFC 219, entered his Octagon debut on a nine-fight winning streak. He owns a 12-2 professional record overall.
USADA announced today that Michał Oleksiejczuk, of Cyców, Poland, has accepted a one-year sanction for a violation of the UFC® Anti-Doping Policy after testing positive for a prohibited substance.
Oleksiejczuk, 23, tested positive for clomiphene following an in-competition urine test conducted on December 30, 2017, at UFC 219 in Las Vegas, Nev. Clomiphene is a Specified Substance in the category of Hormone and Metabolic Modulators and is prohibited at all times under the UFC Anti-Doping Policy, which has adopted the WADA Prohibited List.
Oleksiejczuk’s one-year period of ineligibility began on December 30, 2017, the date his positive sample was collected, and is identical in length to the sanction imposed by the Nevada State Athletic Commission (NSAC) on March 13, 2018. In addition, the NSAC overturned Oleksiejczuk’s victory at UFC 219 to a no-contest.
Pursuant to the UFC Anti-Doping Policy, all UFC athletes serving a period of ineligibility for an anti-doping policy violation are required to continue to make themselves available for testing in order to receive credit for time completed under their sanction.
The sanction is the same length of the one handed down by the Nevada Athletic Commission earlier this year. The NAC also fined Oleksiejczuk 30 percent of his $12,000 purse and overturned his decision victory over Khalil Rountree to a no contest.
Advertisement
Oleksiejczuk, who was a short-notice replacement for Gokhan Saki at UFC 219, entered his Octagon debut on a nine-fight winning streak. He owns a 12-2 professional record overall.
The USADA statement is as follows:
USADA announced today that Michał Oleksiejczuk, of Cyców, Poland, has accepted a one-year sanction for a violation of the UFC® Anti-Doping Policy after testing positive for a prohibited substance.
Oleksiejczuk, 23, tested positive for clomiphene following an in-competition urine test conducted on December 30, 2017, at UFC 219 in Las Vegas, Nev. Clomiphene is a Specified Substance in the category of Hormone and Metabolic Modulators and is prohibited at all times under the UFC Anti-Doping Policy, which has adopted the WADA Prohibited List.
Oleksiejczuk’s one-year period of ineligibility began on December 30, 2017, the date his positive sample was collected, and is identical in length to the sanction imposed by the Nevada State Athletic Commission (NSAC) on March 13, 2018. In addition, the NSAC overturned Oleksiejczuk’s victory at UFC 219 to a no-contest.
Pursuant to the UFC Anti-Doping Policy, all UFC athletes serving a period of ineligibility for an anti-doping policy violation are required to continue to make themselves available for testing in order to receive credit for time completed under their sanction.
Related Articles
